Jubilant Epipad LLC
Balance Sheet as at 31 March 2026

	Notes	As at 31 March 2026	As at 31 March 2025
			USD
ASSETS			
Non-current assets			
Intangible asset under development	3	8,430,234	8,224,755
Total non-current assets		**8,430,234**	**8,224,755**
Current assets			
Financial assets			
i. Cash and cash equivalents	4	18,160	49,942
Total current assets		**18,160**	**49,942**
Total assets		**8,448,394**	**8,274,697**
EQUITY AND LIABILITIES			
Equity			
Equity share capital	5	8,889,230	8,731,230
Other equity		(1,057,015)	(1,053,477)
Total Equity		**7,832,215**	**7,677,753**
LIABILITIES			
Current liabilities			
Financial liabilities			
i. Trade payables	6	616,179	596,944
Total current liabilities		**616,179**	**596,944**
Total liabilities		**616,179**	**596,944**
Total equity and liabilities		**8,448,394**	**8,274,697**

Shyam Pattabiraman

Director

Place: Yardley, Pennsylvania
Date: 18 May 2026

Anuj Mohnot

Director

Place: Yardley, Pennsylvania
Date: 18 May 2026

Jubilant Epipad LLC
Statement of Profit and Loss for the year ended 31 March 2026

	Notes	For the year ended 31 March 2026	For the year ended 31 March 2025
			USD
Revenue from operations		-	-
Other income	7	632	1,474
Total income		**632**	**1,474**
Expenses			
Other expenses	8	4,170	4,487
Total expenses		**4,170**	**4,487**
Loss before exceptional items and tax			
Exceptional items			
(Loss)/ profit before tax		**(3,538)**	**(3,013)**
Tax expense			
- Current tax			-
- Deferred tax			-
Total tax expense		-	-
(Loss)/ profit for the year		**(3,538)**	**(3,013)**
Total comprehensive (loss)/ income for the year		**(3,538)**	**(3,013)**

Shyam

Anuj. Mohnot.

Shyam Pattabiraman
Director

Place: Yardley, Pennsylvania
Date: 18 May 2026

Anuj Mohnot
Director

Place: Yardley, Pennsylvania
Date: 18 May 2026

Jubilant Epipad LLC
Statement of changes in equity for the year ended 31 March 2026

A) Equity share capital

	USD
Balance as at 1 April 2024	**8,006,230**
Additions during the year	725,000
Balance as at 31 March 2025	**8,731,230**
Additions during the year	158,000
Balance as at 31 March 2026	**8,889,230**

B) Other equity

		USD
	Reserves and Surplus	
	Retained earnings	**Total**
Balances as at 1 April 2024	**1,050,464**	**1,050,464**
Total comprehensive loss for the year	3,013	3,013
Balances as at 31 March 2025	**1,053,477**	1,053,477
Total comprehensive loss for the year	3,538	3,538
Balances as at 31 March 2026	**1,057,015**	**1,057,015**

Shyam Pattabiraman
Director

Place: Yardley, Pennsylvania
Date: 18 May 2026

Anuj Mohnot
Director

Place: Yardley, Pennsylvania
Date: 18 May 2026

Jubilant Epipad LLC
Statement of Cash Flows for the year ended 31 March 2026

	For the year ended 31 March 2026	For the year ended 31 March 2025
A. Cash flow from operating activities		
Profit/(Loss) before tax	(3,538)	(3,013)
Operating cash flow before working capital changes	**(3,538)**	**(3,013)**
(Decrease)/Increase in trade payables, provisions and other liabilities	19,235	3,411
Cash generated from/(used in) operations	**15,697**	**398**
Net cash generated from/(used in) operating activities	**15,697**	**398**
B. Cash flow from investing activities		
Purchase of intangible assets (including capital work-in-progress and intangible asset under development)	(205,479)	(680,698)
Net cash used in investing activities	**(205,479)**	**(680,698)**
C. Cash flow arising from financing activities		
Proceeds from issuance of equity	158,000	725,000
Net cash generated from financing activities	**158,000**	**725,000**
D. Effect of exchange rate changes		
Net increase in cash and cash equivalents (A+B+C+D)	**(31,782)**	**44,700**
Add: cash and cash equivalents at the beginning of year	49,942	5,242
Cash and cash equivalents at the end of the year	**18,160**	**49,942**

Shyam Anuj Mohnot

Shyam Pattabiraman
Director

Place: Yardley, Pennsylvania
Date: 18 May 2026

Anuj Mohnot
Director

Place: Yardley, Pennsylvania
Date: 18 May 2026

1. **Corporate information**

Jubilant Epipad LLC. (“the Company”) was incorporated in United States of America under the local laws of Delaware on 19 February 2019. The Company is a fully owned subsidiary of Jubilant Therapeutics India Limited. The Company will focus on the discovery and development of novel drugs for the treatment of cancer in the area of Oncology and Auto-Immune

2. **Significant accounting policies**

This note provides a list of the significant accounting policies adopted in the preparation of these Standalone Financial Statements (“standalone financial statements”).

(a) **Basis of preparation**

(i) Statement of compliance

These standalone financial statements have been prepared solely for the purpose of submission of Annual Performance Report to the Reserve Bank of India, in accordance with Indian Accounting Standards (Ind AS) issued by the Institute of Chartered Accountants of India (ICAI).

(ii) Historical cost convention

The Standalone financial statements have been prepared under historical cost convention on accrual basis, unless otherwise stated.

(b) Functional and presentation currency

Items included in the financial statements of the Company are measured using the currency of the primary economic environment in which the entity operates (i.e. the "functional currency"). The functional currency of the Company is U.S. Dollars (“USD”). These financial statements are presented in USD

(c) **Current versus non-current classification**

The Company presents assets and liabilities in the Standalone Balance Sheet based on current/ non-current classification.

An asset is treated as current when:
- It is expected to be realized or intended to be sold or consumed in normal operating cycle;
- It is held primarily for the purpose of trading;
- It is expected to be realized within twelve months after the reporting period; or
- It is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period

·

Current assets include the current portion of non-current financial assets.

The Company classifies all other assets as non-current.

A liability is current when:

- It is expected to be settled in normal operating cycle;
- It is held primarily for the purpose of trading;

Place: New Jersey

- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period.

The Company classifies all other liabilities as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities respectively.

The operating cycle is the time between the acquisition of assets for processing and their realisation in cash and cash equivalents. The Company has identified period less than twelve months as its operating cycle for the purpose of current/non-current classification of assets and liabilities.

Jubilant Epipad LLC
Notes to the financial statements for the year ended 31 March 2026

Note 3: Intangible asset under development

		USD
	As at 31 March 2026	**As at 31 March 2025**
Intangible asset under development	8,430,234	8,224,755
Total Intangible asset under development	**8,430,234**	**8,224,755**

Note 4: Cash and cash equivalents

		USD
	As at 31 March 2026	**As at 31 March 2025**
Balances with banks		
In current accounts	18,160	49,942
Total cash and cash equivalents	**18,160**	**49,942**

Note 5: Equity share capital

		USD
	As at 31 March 2026	**As at 31 March 2025**
Issued, subscribed and paid up		
Equity shares	8,889,230	8,731,230

1) The Company has only one class of shares referred to as equity shares having no par value. Each holder of equity shares is entitiled to one vote per share.

2) In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company after distribution of all preferential amounts, if any, in proportion to their shareholding. However no such preferential amounts exist currently.

3) The details of shareholders holding more than 5% units in the Company:

	As at 31 March 2026		**As at 31 March 2025**	
	No of units	**% holding in the class**	**No of units**	**% holding in the class**
Name of the Shareholder				
Jubilant Therapeutics Inc	100.00	100%	100	100%

4) The reconciliation of the number of units outstanding as at beginning and at end of the reporting period

	As at 31 March 2026		**As at 31 March 2025**	
	No of units	**USD**	**No of units**	**USD**
Numbers of units at the beginning of the year	100.00	8,731,230	100	8,006,230
Add: Units issued during the year	-	158,000	-	725,000
Number of units at the end of the year	**100**	**8,889,230**	**100**	**8,731,230**

	As at 31 March 2026	**As at 31 March 2025**
	No of units	**No of units**
Numbers of units at the beginning of the year	100	100
Add: Units issued during the year	-	-
Number of units at the end of the year	**100**	**100**

5) Equity shares held by holding company/ultimate holding company is set out below:

Particulars	**As at 31 March 2026**	**As at 31 March 2025**
Jubilant Therapeutics Inc.	100	100

Note 6: Trade payables

	USD	USD
	As at 31 March 2026	**As at 31 March 2025**
Trade payables	1,495	14,243
Due to related parties	614,684	582,701
Total trade payables	**616,179**	**596,944**

Jubilant Epipad LLC
Notes to the financial statements for the year ended 31 March 2026

Note 7: Other Income

	USD	USD
	As at 31 March 2026	**As at 31 March 2025**
Interest Income	553	1,182
Excahnge gain	79	291
Total other Income	**632**	**1,474**

Note 8: Other expenses

		USD
	As at 31 March 2026	**As at 31 March 2025**
Bank charges	4,170	4,486
Total other expenses	**4,170**	**4,486**